Trial | NCT04122222  Report issue

Title

Immune Response to Influenza Vaccine in ESRD Patients
Immune Response to Influenza Vaccination in ESRD Patients Undergoing Hemodialysis vs. Hemodiafiltration

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    60
On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.
Study Started
Aug 25
2016
Primary Completion
Jul 20
2018
Study Completion
Jul 20
2018
Last Update
Oct 10
2019

Biological Influenza vaccine

A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.

  • Other names: A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.

Hemodialysis Active Comparator

ESRD patients treated by hemodialysis

Hemodiafiltration Active Comparator

ESRD patients treated by on-line hemodiafiltration

Criteria 

Inclusion Criteria:

- ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group

Exclusion Criteria:

Had received any vaccination within the previous four weeks, or influenza vaccination within six months
Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination
A history of allergy to influenza vaccine or egg
Thrombocytopenia
In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency
No Results Posted